The centre will help progress the very latest scientific research findings from the University into enhanced treatments for patients across a range of major health issues including cancer and liver disease.
The Institute will build on Birmingham’s excellent track record in clinical trials by increasing capacity and enabling more patients to be co-located alongside clinicians and researchers. It will also make it easier for both SME and large pharma and biotechnology firms to work more closely with clinicians and academics, bringing additional investment into the city.
The new ITM facility is a part of a hospital trust masterplan (also developed by Glenn Howells Architects) and will contain office space, laboratories and collaborative working areas, as well as a clinical trials facility. The building will retain its existing stripped-back Art Deco façade with the internal spaces reconfigured as four wings set around a newly in-filled courtyard.
The project received planning permission in December and work commenced on site at the beginning of May and represents the first healthcare development for Glenn Howells Architects.